
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Celiac disease-related conditions: Who to test?</title>
<style>

<style>
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #f0f4ff, #fafafa);
    color: #2c2c2c;
    padding: 40px;
}

/* Mindmap container */
.mindmap {
    max-width: 900px;
    margin: auto;
    font-size: 16px;
    line-height: 1.7;
}

.mindmap ul {
    margin: 0.5em 0 1em 1em;
    padding-left: 1.5em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #a855f7; /* prettier bullets */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}


/* Collapsible sections */
.mindmap details {
    border-left: 4px solid #8b5cf6;
    background: #ffffff;
    margin: 15px 0;
    padding: 16px 20px;
    border-radius: 16px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.12);
    transition: all 0.3s ease;
    position: relative;
}

/* Hover glow */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.2);
    background: linear-gradient(135deg, #ffffff, #f3f0ff);
}

/* Summary styling */
.mindmap summary {
    cursor: pointer;
    font-size: 1.15em;
    font-weight: 600;
    list-style: none;
    position: relative;
    padding-left: 28px;
    color: #4c1d95;
}

/* Custom arrow */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Titles */
.mindmap summary strong {
    display: block;
    font-size: 1.3em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Description bullets */
.mindmap ul {
    padding-left: 22px;
    margin-top: 10px;
    margin-bottom: 12px;
}

.mindmap li {
    margin-bottom: 6px;
    font-size: 0.97em;
    color: #444;
    list-style-type: disc;
    position: relative;
    padding-left: 4px;
}

/* Nesting indent style */
.mindmap details > div > details {
    margin-left: 20px;
    border-color: #a855f7;
    background: #f9f5ff;
}

/* Fade-in effect */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* Description box */
.mindmap .desc-box {
    background: #fdfcff;
    border: 1px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 4px 6px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.06);
    transition: background 0.3s ease;
}

.mindmap .desc-box:hover {
    background: #f9f4ff;
}


button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease;
}
button:hover {
    background-color: #6b21a8;
}


@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}


#level-controls button {
    background-color: rgba(124, 58, 237, 0.7); /* semi-transparent purple */
    color: white;
    border: none;
    padding: 8px 14px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s;
}

#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.85); /* slightly darker on hover */
    transform: scale(1.05);
}

#level-controls {
    position: fixed;
    bottom: 20px;
    left: 50%;
    transform: translateX(-50%);
    background: rgba(124, 58, 237, 0.1);
    padding: 8px 14px;
    border-radius: 12px;
    box-shadow: 0 4px 10px rgba(0, 0, 0, 0.1);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move; /* shows move cursor */
}

</style>




</style>
</head>
<body>
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="setMindmapLevel(1)">Level 1</button>
    <button onclick="setMindmapLevel(2)">Level 2</button>
    <button onclick="setMindmapLevel(3)">Level 3</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>Celiac disease-related conditions: Who to test?</strong></summary>
            <div>
                <ul><li>Authors: Fabiana Zingone, Julio C. Bai, Christophe Cellier, Jonas F. Ludvigsson</li><li>Journal: Gastroenterology</li><li>Publication Date: Accepted Date 15 February 2024</li><li>DOI: https://doi.org/10.1053/j.gastro.2024.02.044</li><li>Target Audience: Physicians</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>1. What percentage of the general population is estimated to have celiac disease?</li><li>2.  Name three conditions where CeD screening is recommended due to high CeD prevalence.</li><li>3.  What is the pooled prevalence of biopsy-verified CeD in Autoimmune Hepatitis (AIH)?</li><li>4.  What specific serological test is crucial to perform in IgA-deficient individuals suspected of having CeD?</li><li>5.  In first-degree relatives of individuals with CeD, what is the pooled prevalence of CeD?</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Abstract</strong></summary>
            <div>
                <ul><li>CeD is a chronic immune-mediated condition ← gluten consumption in genetically predisposed individuals.</li><li>Affects ≈1% of general population.</li><li>Effective strategy for identifying undiagnosed CeD: proactive case-finding via serologic testing in high-risk groups.</li></ul>
                
        <details>
            <summary><strong>Recommendations for CeD Screening</strong></summary>
            <div>
                <ul><li>Screening recommended in individuals w/:</li><li>Autoimmune disease + symptoms suggestive of CeD.</li><li>Diseases mimicking CeD (IBS, IBD, MC).</li><li>Conditions w/ high CeD prevalence (first-degree relatives, idiopathic pancreatitis, unexplained liver enzyme abnormalities, AIH, PBC, hyposplenism, T1DM, Hashimoto’s thyroiditis, Grave’s disease, SjS, DH, recurrent aphthous syndrome, enamel defects, unexplained ataxia, peripheral neuropathy, delayed menarche, premature menopause, Down syndrome, Turner syndrome, Williams syndrome, chronic fatigue syndrome, IgA nephropathy, IgA deficiency).</li></ul>
                
        <details>
            <summary><strong>Initial Step</strong></summary>
            <div>
                <ul><li>CeD serology = initial step in screening process.</li><li>Patients undergoing upper endoscopy for any reason: biopsies should be performed to rule out CeD.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Introduction</strong></summary>
            <div>
                <ul><li>CeD: immune-mediated disorder affecting ≈1% of general population.</li><li>Characterized by enteropathy w/ systemic involvement + antibody formation.</li><li>Underdiagnosis ← wide spectrum of symptoms (classical CeD to asymptomatic cases). Many individuals first manifest CeD through an associated disorder.</li></ul>
                
        <details>
            <summary><strong>Mechanisms of Association</strong></summary>
            <div>
                <ul><li>Chronic inflammation + immune-mediated damage of small intestinal mucosa → villus atrophy → impaired nutrient absorption → malnutrition, fatigue, weight loss, nutritional deficiencies.</li><li>Villus atrophy impairs calcium &amp; vitamin D absorption → hypocalcemia &amp; ↑ PTH levels.</li><li>↑ PTH → bone resorption &gt; new bone formation → net bone loss. Persistent villus atrophy linked to ↑ risk of hip fractures.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Genetic Predisposition</strong></summary>
            <div>
                <ul><li>HLA class II genes on chromosome 6p21 (DR, DQ, DP loci) play crucial role in CeD etiology.</li><li>Twin studies report high heritability.</li><li>Presence of HLA molecules linked to CeD = prerequisite for development. These molecules prevalent in general population (30-40%) but not diagnostic markers.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Mendelian Randomization</strong></summary>
            <div>
                <ul><li>Recent research using Mendelian randomization: relationship between CeD and several autoimmune diseases: Crohn’s disease, PBC, rheumatoid arthritis, systemic lupus erythematosus, T1DM, asthma.</li><li>Shared genetic backgrounds (DQ2 &amp; DQ8 positivity) extensively documented in T1DM &amp; CeD.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Chronic Inflammation and Cancer Risk</strong></summary>
            <div>
                <ul><li>Chronic inflammation in small intestine = risk factor for cancer.</li><li>Swedish study: ↑ risk of lymphoproliferative malignancies in individuals w/ persistent villus atrophy vs. those w/ healed mucosa.</li><li>Non-adherence to GFD may ↑ risk of cancer &amp; mortality.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Diagnostic Tools</strong></summary>
            <div>
                <ul><li>Introduction of CeD serology allows wider screening.</li><li>Diagnostics involve clinical, serological, genetic, &amp; histological factors.</li><li>Distinct clinical scenarios warrant investigation for CeD; Table 1 summarizes guidelines for identifying CeD in high-risk individuals &amp; special situations.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Paper Objective</strong></summary>
            <div>
                <ul><li>Examination of screening for CeD in &gt;30 conditions.</li><li>Provide evidence-based recommendations for screening (Table 2, Figure 1).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Irritable Bowel Syndrome (IBS)</strong></summary>
            <div>
                <ul><li>IBS: disorder of gut-brain interaction (DGBI) affecting 1.5% to 10.1% of Western population.</li><li>CeD prevalence in IBS patients varies across studies &amp; regions.</li><li>Many CeD patients encounter IBS symptoms during follow-up, sometimes ← gluten cross-contamination. Some individuals may experience IBS symptoms independent of gluten.</li></ul>
                
        <details>
            <summary><strong>Guidelines</strong></summary>
            <div>
                <ul><li>Recent international guidelines suggest CeD be ruled out in all functional bowel disorders accompanied by diarrhea.</li><li>Some guidelines recommend serological screening in all patients w/ IBS symptoms independent of stool pattern.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Meta-Analysis</strong></summary>
            <div>
                <ul><li>Recommendation to conduct screening for CeD partially grounded on meta-analysis of 36 studies (n=15,256 individuals, 9,275 fulfilling IBS criteria).</li><li>OR for biopsy-confirmed CeD in IBS = 4.48.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Recommendation</strong></summary>
            <div>
                <ul><li>Patients presenting w/ IBS-like symptoms should undergo screening for CeD.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Type 1 Diabetes Mellitus (T1DM)</strong></summary>
            <div>
                <ul><li>Evidence suggests incidence of CeD has increased.</li><li>Recent data indicate 8 million people suffer from T1DM (2021).</li><li>T1DM has strong genetic component (mainly DR3-DQ2 &amp; DR4-DQ8).</li></ul>
                
        <details>
            <summary><strong>Finnish Study</strong></summary>
            <div>
                <ul><li>Nationwide Finnish study: 1 in 5 individuals w/ T1DM had ≥1 other autoimmune disease.</li><li>Compared to diabetes-free controls, Finns w/ T1DM were at 4.6-fold ↑ risk of CeD.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Meta-Analyses</strong></summary>
            <div>
                <ul><li>Several meta-analyses conclude CeD more prevalent in T1DM, w/ pooled prevalence rates ranging from 5.1% to 6.0%.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Importance of Detection</strong></summary>
            <div>
                <ul><li>Detecting CeD in T1DM important ∵ potential impact of celiac comorbidity on long-term prognosis of T1DM.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>GFD Impact</strong></summary>
            <div>
                <ul><li>Supported by a screening study of &gt;1000 asymptomatic TIDM patients, treatment w/ GFD adds to burden of T1DM but seems to have no major negative effects on HbA1c levels, hypoglycemia episodes, &amp; growth in young people.</li><li>However, Mahumud FH et al failed to demonstrate a lower HbA1C in asymptomatic T1DM+ CeD patients randomized to a GFD compared to those who continued on a normal diet.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Screening Recommendation</strong></summary>
            <div>
                <ul><li>Individuals w/ T1DM should be screened for CeD.</li><li>∵ CeD can manifest at any time &amp; w/ greater frequency during initial 5 years, conducting additional screenings in CeD-negative T1DM patients 2 &amp; 5 years after T1DM diagnosis &amp; those who later develop GI symptoms may be advisable.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Autoimmune Hepatitis and Unexplained Liver Enzyme Abnormalities</strong></summary>
            <div>
                <ul><li>AIH: progressive autoimmune liver disorder → inflammation → cirrhosis w/ liver failure.</li><li>AIH linked to several autoimmune conditions.</li><li>CeD prevalence has ranged from just above general population (≈1%) to 1 in 5 individuals in AIH (2-20%).</li></ul>
                
        <details>
            <summary><strong>Meta-Analysis</strong></summary>
            <div>
                <ul><li>Recent meta-analysis: 15 relevant studies identified, 8 included in main analysis.</li><li>Pooled prevalence of biopsy-verified CeD in AIH = 3.5% (95% CI = 1.6-5.3%).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Elevated Liver Enzymes</strong></summary>
            <div>
                <ul><li>CeD may also present through elevated liver enzymes (aminotransferases), often asymptomatic.</li><li>Two mechanisms: cryptogenic liver disease (normalizes w/ GFD) &amp; autoimmunity (AIH, both CeD &amp; liver disease must be treated).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Meta-Analysis (Elevated Liver Enzymes)</strong></summary>
            <div>
                <ul><li>One meta-analysis suggested 5-6% of patients w/ elevated transaminases but no other known cause have biopsy-confirmed CeD.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Recommendations</strong></summary>
            <div>
                <ul><li>Individuals w/ AIH should be screened for CeD (ideally before steroids/immunosuppressives).</li><li>Patients w/ unexplained elevated liver enzymes should be screened.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Inflammatory Bowel Disease</strong></summary>
            <div>
                <ul><li>Both CeD &amp; IBD are immune-mediated diseases.</li><li>Immunologically, patients w/ CeD &amp; ulcerative colitis, but not Crohn’s disease, are prone to develop autoantibodies.</li><li>CeD &amp; ulcerative colitis may also share genetic risk factors.</li></ul>
                
        <details>
            <summary><strong>Meta-Analysis</strong></summary>
            <div>
                <ul><li>Meta-analysis of &gt;60 studies (2020): risk ratio of 4.0 for CeD in IBD patients.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Swedish Study</strong></summary>
            <div>
                <ul><li>Mårild et al.: 48,551 individuals w/ CeD were at 3.9-fold ↑ risk of later IBD.</li><li>Mårild also reported 2.4% of all diagnosed IBD patients in Sweden also had CeD.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Kori et al.</strong></summary>
            <div>
                <ul><li>Kori et al.: OR for CeD ≈ 3 in patients w/ IBD compared to controls.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Sonnenberg and Genta</strong></summary>
            <div>
                <ul><li>Sonnenberg &amp; Genta (Inform Diagnostics database): inverse relationship between IBD &amp; CeD (OR=0.50; 95%CI=0.38-0.64). Limited to people who underwent bidirectional endoscopy on same day.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Potential Causes</strong></summary>
            <div>
                <ul><li>Elevated risk of CeD in IBD: some individuals w/ IBD screened for CeD exclusively after IBD diagnosis.</li><li>CeD may develop later in life, possibly triggered by inflammation of IBD or shared trigger.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Recommendation</strong></summary>
            <div>
                <ul><li>IBD patients should be screened for CeD, especially those who do not respond well to treatment.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Eosinophilic Esophagitis</strong></summary>
            <div>
                <ul><li>EoE: clinicopathological disorder characterized by esophageal dysfunction &amp; eosinophilic inflammation (typically ≥15 eosinophils/high-power microscopy field).</li><li>Rise in reported cases of EoE.</li><li>Immunological background may differ from CeD (Th2 vs Th1), but symptoms may be comparable (dysphagia, feeding difficulties, vomiting, abdominal discomfort).</li></ul>
                
        <details>
            <summary><strong>Diagnostic Procedure</strong></summary>
            <div>
                <ul><li>Usual diagnostic procedure for CeD &amp; EoE requires upper endoscopy.</li><li>Procedure will ↑ likelihood that a patient is diagnosed w/ CeD, even if symptoms related to EoE. Diagnostic work-up will automatically strengthen any disease association.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Meta-Analyses</strong></summary>
            <div>
                <ul><li>While several studies suggested ↑ risk of CeD in EoE patients, few used control groups.</li><li>First meta-analysis underlined limitations of earlier research.</li><li>Second meta-analysis (&gt;10,000 children undergoing endoscopy) found no association between CeD &amp; EoE.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Recommendation</strong></summary>
            <div>
                <ul><li>Patients w/ EoE should not undergo screening for CeD.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Microscopic Colitis</strong></summary>
            <div>
                <ul><li>MC: disease of middle old age, w/ female predominance.</li><li>Common symptoms: watery diarrhea, overlaps w/ presentation of CeD in some individuals.</li><li>Collagenous colitis &amp; CeD share genetic predisposition.</li></ul>
                
        <details>
            <summary><strong>Genetic Link</strong></summary>
            <div>
                <ul><li>MC linked to DQB1_201, also seen in CeD.</li><li>Not possible to assert that shared genes are exclusive to collagenous colitis or relevant to lymphocytic colitis ∵ limited research.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Danish Data</strong></summary>
            <div>
                <ul><li>Danish data reported 10-fold ↑ in CeD in patients w/ MC.</li><li>Assuming most MC patients underwent CeD testing, reported prevalence of CeD in this Danish cohort was not higher than expected for general population (1%).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Bergman et al.</strong></summary>
            <div>
                <ul><li>Bergman et al. followed-up &gt;45,000 individuals w/ CeD &amp; 224,000 reference individuals to examine future risk of MC.</li><li>Found that a higher proportion of MC patients had a CeD diagnosis compared to Danish patient population.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>ESPRESSO Cohort</strong></summary>
            <div>
                <ul><li>Extrapolating from another MC study obtained from ESPRESSO cohort, ≈3% of Swedish MC patients were diagnosed w/ CeD at some point.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Recommendation</strong></summary>
            <div>
                <ul><li>Despite limited data on actual prevalence of CeD in patients w/ MC, guidelines recommend to screen for CeD at work-up for MC.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Hyposplenism or Functional Asplenia</strong></summary>
            <div>
                <ul><li>Hyposplenism linked to CeD.</li><li>Prevalence ↑ from 19% in patients w/ uncomplicated CeD to 59% in those w/ CeD &amp; other autoimmune diseases &amp; up to 80% in those CeD patients who had premalignant or malignant complications.</li></ul>
                
        <details>
            <summary><strong>GFD Effect</strong></summary>
            <div>
                <ul><li>GFD effective in restoring splenic function, except in patients w/ irreversible loss of splenic tissue.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Risk of Infections</strong></summary>
            <div>
                <ul><li>Hyposplenism &amp; functional asplenia are potential factors contributing to ↑ risk of severe bacterial infections in CeD in children &amp; adults, particularly those associated w/ encapsulated bacteria; risks persist even years after CeD diagnosis.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Recommendation</strong></summary>
            <div>
                <ul><li>Absence of definitive evidence necessitates restricting screening to patients w/ confirmed hyposplenism &amp; severe bacterial infections.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Unexplained Amylase/Pancreatic Enzyme Abnormalities</strong></summary>
            <div>
                <ul><li>Pancreatic dysfunction, including exocrine pancreatic insufficiency (seen in 26.2% of patients w/ newly diagnosed CeD), CAPH, &amp; AP have been associated w/ CeD.</li><li>No association between autoimmune pancreatitis &amp; CeD has been described.</li></ul>
                
        <details>
            <summary><strong>CAPH</strong></summary>
            <div>
                <ul><li>Reports on CeD have yielded contradictory results for CAPH.</li><li>Study by Carroccio et al. found CAPH prevalence of ≈25% in childhood &amp; adult CeD.</li><li>Investigation for CeD in 65 CAPH patients yielded predominantly negative results.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Recurrent Abdominal Pain</strong></summary>
            <div>
                <ul><li>Prospective study of 169 patients w/ recurrent abdominal pain suggestive of pancreatic disease found that 12 (7.1%) had histological evidence consistent w/ CeD.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Swedish Registers</strong></summary>
            <div>
                <ul><li>Two studies from Swedish national registers showed almost 3-fold ↑ in risk of developing pancreatitis in patients w/ CeD.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Etiology of Pancreatitis</strong></summary>
            <div>
                <ul><li>SadrAzodi et al. showcased ↑ risk of non-gallstone AP in CeD patients after adjusting for alcohol-related disorders.</li><li>Ludvigsson et al. showed ↑ risk of AP after accounting for high alcohol consumption &amp; gallstone disease.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>US Population Database</strong></summary>
            <div>
                <ul><li>Extensive US population database recently found ↑ risk of new diagnosis of acute &amp; chronic pancreatitis in CeD patients within 1 month of diagnosis. Idiopathic AP was most common etiology in CeD patients.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Recommendation</strong></summary>
            <div>
                <ul><li>Patients w/ unexplained pancreatitis should be screened for CeD.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Autoimmune Atrophic Gastritis</strong></summary>
            <div>
                <ul><li>Prevalence of CeD in autoimmune atrophic gastritis is variable, ranging from 2.1-9.1%.</li><li>Estimates include newly diagnosed cases &amp; already established CeD.</li></ul>
                
        <details>
            <summary><strong>Recommendation</strong></summary>
            <div>
                <ul><li>Current evidence supports CeD screening in patients w/ autoimmune atrophic gastritis.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Psoriasis and Other Skin Disorders</strong></summary>
            <div>
                <ul><li>Psoriasis: chronic inflammatory disease affecting ≈2% of population, characterized by well-demarcated, erythematous, scaly plaques.</li></ul>
                
        <details>
            <summary><strong>Meta-Analysis</strong></summary>
            <div>
                <ul><li>Meta-analysis (nine studies w/ 136,536 cases &amp; 5,716,558 controls) found double risk of earlier CeD in psoriasis (OR=2.16; 95%CI=1.74-2.69).</li><li>No association seen between psoriasis &amp; later CeD.</li><li>CeD patients were 1.8-fold more likely to have psoriasis, &amp; CeD patients had 1.7 times higher risk of developing new-onset psoriasis.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Population-Based Cohort Study</strong></summary>
            <div>
                <ul><li>Population-based cohort study of patients w/ histologically confirmed CeD evaluated risk of skin disorders in patients w/ CeD (n=43,300) compared to comparators (n=198,532).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Skin Disorders and CeD</strong></summary>
            <div>
                <ul><li>Strong association w/ DH (HR=70.42; 95%CI=46.62-106.39).</li><li>Positive association between CeD &amp; all examined skin disorders (eczema, psoriasis, urticaria, vitiligo, acne, &amp; alopecia areata), but w/ moderate risk estimates (ranging from acne (HR=1.39) to vitiligo (HR=1.90)). Part of association may be coincidental.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Atopic Dermatitis</strong></summary>
            <div>
                <ul><li>Two recent studies confirmed association between CeD &amp; atopic dermatitis, although w/ different risk estimates (OR=1.61 &amp; 4-fold ↑ risk of later CeD in children w/ AD).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Chronic Urticaria</strong></summary>
            <div>
                <ul><li>Two other studies demonstrated link w/ chronic urticaria.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Meta-Analysis (Oral Disorders)</strong></summary>
            <div>
                <ul><li>Meta-analysis demonstrated higher risk of recurrent aphthous syndrome in CeD patients (OR=3.79, 95%CI=2.67–5.3), confirmed in children &amp; adults.</li><li>Enamel defects also observed (OR=5.69, 95%CI=3.47-9.33), but only in children.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Recommendations</strong></summary>
            <div>
                <ul><li>Noticeable associations exist between CeD &amp; various skin disorders, but associations tend to be of moderate strength.</li><li>Screening for CeD should be performed in all patients w/ recurrent aphthous syndrome &amp; enamel defects.</li><li>Screenings for other skin disorders (eczema, psoriasis, urticaria, vitiligo, acne, &amp; alopecia areata) exclusively in cases where there is indication of ↑ risk of CeD based on GI symptoms or additional information.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Dermatitis Herpetiformis</strong></summary>
            <div>
                <ul><li>DH commonly regarded as cutaneous manifestation of CeD, triggered by gluten &amp; improved by GFD.</li><li>CeD serology is widely recommended.</li><li>Rare skin presentation represents most frequent skin disorder in CeD.</li></ul>
                
        <details>
            <summary><strong>Characteristics</strong></summary>
            <div>
                <ul><li>DH characterized by intensely pruritic papules &amp; vesicles, primarily on extensor surfaces such as elbows, knees, buttocks, or lower back.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Osteopenia, Osteoporosis, and Risk of Bone Fractures</strong></summary>
            <div>
                <ul><li>Both osteopenia &amp; osteoporosis have been linked to CeD, &amp; patients w/ CeD seem to be at ↑ risk of fractures.</li><li>Lack of consensus regarding potential risk of CeD in patients w/ osteopenia/osteoporosis.</li></ul>
                
        <details>
            <summary><strong>Stenson et al.</strong></summary>
            <div>
                <ul><li>Stenson et al. reported higher occurrence of CeD (3.4%) in post-menopausal women compared to women w/o osteoporosis (0.2%), leading authors to recommend serological screening for CeD in all osteoporosis patients.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Meta-Analysis</strong></summary>
            <div>
                <ul><li>Comprehensive meta-analysis of &gt;3000 patients, prevalence of CeD (1.6%) was only marginally higher compared to general population.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Netherlands Data</strong></summary>
            <div>
                <ul><li>Recent data from Netherlands emphasized lack of definitive link between CeD &amp; fractures.</li><li>In fracture patients, only 0.38% found to have biopsy-proven CeD, aligns w/ anticipated prevalence of CeD in Western Europe. Study did not recommend screening for CeD in middle-aged patients w/ fractures.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Recommendation</strong></summary>
            <div>
                <ul><li>Screening for CeD should only be performed in patients w/ osteoporosis/osteopenia if they exhibit additional signs of CeD.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Chronic Fatigue</strong></summary>
            <div>
                <ul><li>Chronic fatigue syndrome characterized by overwhelming sense of tiredness, lack of energy, &amp; persistent &amp; prolonged exhaustion, even after rest.</li><li>Syndrome associated w/ systemic immune activation &amp; frequently reported in CeD.</li></ul>
                
        <details>
            <summary><strong>Prevalence</strong></summary>
            <div>
                <ul><li>Previous evidence indicated prevalence of 2-3% of CeD in individuals who present w/ chronic fatigue.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Challenges</strong></summary>
            <div>
                <ul><li>Clinical research encounters challenges ∵ scarcity of published studies, small sample sizes, diverse study designs, &amp; use of unspecified instruments for chronic fatigue measurement. Clinical factors such as depression &amp; anemia can act as confounders.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Literature Review</strong></summary>
            <div>
                <ul><li>Recent literature review suggests prevalence of chronic fatigue varies significantly @ CeD diagnosis &amp; that treatment w/ GFD may have positive impact. However, little data to confirm that GFD improves symptoms in patients w/ CeD.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Recommendation</strong></summary>
            <div>
                <ul><li>Current guidelines suggest CeD screening in patients w/ chronic fatigue. Nonetheless, additional research is needed.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Chromosomal Syndromes</strong></summary>
            <div>
                <ul><li>High prevalence of CeD has been reported in several chromosomal disorders, warranting need for CeD screening in at least three groups: Down syndrome, Turner’s syndrome, &amp; Williams (Beuren) syndrome.</li></ul>
                
        <details>
            <summary><strong>Down Syndrome</strong></summary>
            <div>
                <ul><li>Meta-analysis of 31 studies encompassing 4,383 individuals reported prevalence rate of biopsy-confirmed CeD of 5.8% (95%CI=4.7-7.2%) in patients w/ Down syndrome, particularly in children.</li><li>Retrospective study on 1317 children w/ Down Syndrome, finding 9.8% prevalence of CeD.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Turner&#x27;s Syndrome</strong></summary>
            <div>
                <ul><li>Systematic review &amp; meta-analysis of 36 studies, including 6291 Turner´s syndrome patients, showed crude prevalence of 3.8% in CeD.</li><li>Risk of CeD in females w/ Turner´s syndrome ranged from 2-fold ↑ in first 5 years of life to &gt;5-fold ↑ in females aged &gt;10 years @ CeD diagnosis.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Williams (Beuren) Syndrome</strong></summary>
            <div>
                <ul><li>Studies reported CeD prevalences of 4.1%, 6.9% &amp; 10.8%.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Neurologic Manifestations</strong></summary>
            <div>
                <ul><li>CeD linked to variety of neurological disorders.</li><li>Conditions may present prior to diagnosis of CeD, throughout its progression, &amp; potentially lead to non-compliance w/ treatment, even in absence of typical GI symptoms.</li></ul>
                
        <details>
            <summary><strong>Cicarelli et al.</strong></summary>
            <div>
                <ul><li>Cicarelli et al. found that 27.9% of patients w/ CeD following a GFD exhibited minimum of two of three peripheral neurological symptoms, such as cramps, paresthesia, weakness, reduction of vibratory sense, &amp; hyporeflexia.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Hadjivassiliou et al.</strong></summary>
            <div>
                <ul><li>Hadjivassiliou et al., noted that 67% of patients diagnosed w/ CeD showed signs of neurologic dysfunction, 24% experienced gait instability, 12% had persistent sensory symptoms, &amp; 42% reported frequent headaches; 21% had at least two of these neurologic symptoms.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Gluten Ataxia</strong></summary>
            <div>
                <ul><li>Gluten ataxia characterized by lack of coordination is associated w/ antigliadin antibodies.</li><li>Typically manifests as either pure cerebellar ataxia or, in rare cases, ataxia in combination w/ myoclonus, palatal tremor, opsoclonus, or chorea. Onset commonly insidious, often occurring during adulthood. Few patients w/ gluten ataxia experience GI symptoms, &amp; ≈1/3 will show signs of enteropathy on biopsy. Cerebellar atrophy may be observed in up to 60% of patients w/ gluten ataxia.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Cerebellar Ataxia Study</strong></summary>
            <div>
                <ul><li>Old study w/ small sample size found that 12% of patients w/ cerebellar ataxia w/o confirmed diagnosis had CeD based on serologic &amp; histologic evaluations. However, none of patients w/ genetic or Friedreich’s ataxia met criteria for diagnosis of CeD.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Epilepsy</strong></summary>
            <div>
                <ul><li>Prevalence of epilepsy in CeD estimated to range from 1.2% to 5%.</li><li>Italian &amp; Swedish data showed 1.4- to 2-fold ↑ risk of later epilepsy in CeD patients.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Headache</strong></summary>
            <div>
                <ul><li>Population-based study found that CeD was associated w/ 2-fold ↑ risk of later diagnosis of headache.</li><li>Risk ↑ were seen for migraine (HR=1.67) &amp; unclassified headache (HR=1.67) but not trigeminal neuralgia (HR=1.35).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Recommendations</strong></summary>
            <div>
                <ul><li>Routine screening for CeD recommended in patients w/ peripheral neuropathy &amp; ataxia.</li><li>Connection between CeD &amp; other neurological disorders is evident, but associations tend to be of moderate strength, therefore, epilepsy &amp; headache should only prompt screening in patients w/ concomitant GI symptoms.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Hashimoto’s Thyroiditis and Grave’s Disease</strong></summary>
            <div>
                <ul><li>Prevalence of autoimmune thyroid diseases (Hashimoto’s thyroiditis &amp; Graves’ disease) are ≈2-3% &amp; 1%, respectively, in general population, w/ higher incidence in females.</li></ul>
                
        <details>
            <summary><strong>Swedish Study</strong></summary>
            <div>
                <ul><li>Swedish epidemiological study of 14,021 patients w/ CeD found significant association between CeD &amp; hypothyroidism (HR=4.4, 95%CI=3.4-5.6), thyroiditis (HR=3,6; 95%CI=1.9-6.7), &amp; hyperthyroidism (HR=2.9; 95%CI=2.0-4.2).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Meta-Analysis</strong></summary>
            <div>
                <ul><li>Meta-analysis of 27 studies showed prevalence of biopsy-proven CeD in 6.2% of children &amp; 2.7% of adults w/ autoimmune thyroid disease.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Recommendation</strong></summary>
            <div>
                <ul><li>Suggestion to screen for CeD in patients w/ autoimmune thyroid disease is widely supported.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Primary Biliary Cholangitis</strong></summary>
            <div>
                <ul><li>PBC: chronic cholestatic &amp; autoimmune disease predominantly affecting women.</li><li>Patients have high prevalence of CeD.</li></ul>
                
        <details>
            <summary><strong>Studies</strong></summary>
            <div>
                <ul><li>12-year study in South Wales reported CeD in 4/67 (6%) PBC patients.</li><li>Danish study reported SIR of 27.6 (CI=2.9-133) for PBC in Denmark &amp; 25.1 in Sweden compared to general population.</li><li>Large-scale study confirmed strong association between CeD &amp; later PBC (HR=10.16).</li><li>Smaller study from Crete found no ↑ risk of PBC.</li><li>UK longitudinal primary care study reported 3-fold ↑ risk of PBC compared to general population.</li><li>Literature review found that prevalence of PBC in CeD ranged between 0 &amp; 11%.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Conclusion</strong></summary>
            <div>
                <ul><li>Evidence suggests need to screen patients w/ PBC for CeD.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Sjögren’s Syndrome</strong></summary>
            <div>
                <ul><li>SjS: autoimmune disease characterized by destruction of exocrine glands, leading to ocular &amp; oral sicca.</li><li>Diagnosis based on antibodies &amp; biopsies of salivary gland tissue.</li><li>Celiac seroprevalence (anti-transglutaminase IgA) appears to be more frequent in SJS than in other rheumatic diseases.</li></ul>
                
        <details>
            <summary><strong>Italian Study</strong></summary>
            <div>
                <ul><li>Large multicenter study in Italy found that patients w/ SJS (n=354) showed higher prevalence of CeD than controls (n=14,298) (6.78% vs 0.64%, p&lt;0.0001).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Hungarian Study</strong></summary>
            <div>
                <ul><li>Study of 111 Hungarian patients w/ SJS, a CeD prevalence rate of 4.5% was found.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Finish Study</strong></summary>
            <div>
                <ul><li>Study involving 34 Finish patients diagnosed w/ SJS, five cases of histology-proven CeD were observed (14.7%).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Recommendation</strong></summary>
            <div>
                <ul><li>Current evidence supports CeD screening in all patients w/ SJS.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>IgA Nephropathy</strong></summary>
            <div>
                <ul><li>IgA nephropathy: one of most common kidney diseases worldwide.</li><li>Chronic &amp; lifelong induced by IgA deposits in renal glomeruli, leading to complement activation &amp; injury.</li></ul>
                
        <details>
            <summary><strong>Studies</strong></summary>
            <div>
                <ul><li>Research on CeD &amp; IgA nephropathy has shown 3-fold ↑ risk of IgA nephropathy in CeD patients.</li><li>Study comprised 223 patients w/ IgA nephropathy showed CeD prevalence of 3.6%.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Recommendation</strong></summary>
            <div>
                <ul><li>Patients w/ unexplained IgA nephropathy should undergo screening for CeD.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>IgA Deficiency</strong></summary>
            <div>
                <ul><li>Selective IgAD, isolated IgA deficiency w/ normal IgM &amp; IgG levels, is most common primary immune defect.</li><li>&gt;1 in 4 patients w/ IgAD have concomitant autoimmune disease.</li></ul>
                
        <details>
            <summary><strong>Prevalence in CeD</strong></summary>
            <div>
                <ul><li>Prevalence of IgAD in CeD patients is ≈2%.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Studies</strong></summary>
            <div>
                <ul><li>Study on 65 IgAD children revealed prevalence rate for CeD of 7.7%.</li><li>Swedish study detected 54 biopsy-proven cases of CeD in sera from 356 IgAD patients (15.2%).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Testing Considerations</strong></summary>
            <div>
                <ul><li>Testing only IgA anti-tissue transglutaminase (tTG) may result in false negative CeD serology in individuals w/ IgAD.</li><li>Important to confirm CeD diagnosis in these patients through IgG serology (TTG IgG or DGP IgG) &amp; duodenal biopsy.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Recommendation</strong></summary>
            <div>
                <ul><li>Screening for CeD is advisable for patients w/ IgAD.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Infertility and Recurrent Spontaneous Abortion</strong></summary>
            <div>
                <ul><li>Infertility: failure to conceive after engaging in regular unprotected sexual intercourse for 12 months (WHO definition).</li><li>RSA, occurring in 1 to 2% of all women, determined by presence of two or more consecutive abortions of unknown origin.</li><li>Data on infertility &amp; RSA in CeD are conflicting.</li></ul>
                
        <details>
            <summary><strong>Population-Based Studies</strong></summary>
            <div>
                <ul><li>Three population-based cohort studies found comparable fertility rates in women w/ CeD adhering to GFD &amp; those w/o CeD.</li><li>Data may suggest potential ↓ in fertility for women between 25 &amp; 29 diagnosed w/ CeD (before &amp; after diagnosis).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Meta-Analyses</strong></summary>
            <div>
                <ul><li>Meta-analysis do not suggest ↑ CeD seroprevalence in women w/ unexplained infertility.</li><li>Subsequent meta-analysis (more stringent inclusion criteria) found no association between infertility &amp; CeD.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Pregnancy Manifestation</strong></summary>
            <div>
                <ul><li>Evidence shows that CeD can manifest clinically for first time during pregnancy or in puerperium.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Conclusion</strong></summary>
            <div>
                <ul><li>Women who experience repeated adverse pregnancy outcomes should be screened for CeD; however, screening for CeD should not rely exclusively on infertility.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Delayed Menarche, Premature Menopause</strong></summary>
            <div>
                <ul><li>Data on age at menarche &amp; menopause in CeD are limited &amp; conflicting.</li></ul>
                
        <details>
            <summary><strong>Studies</strong></summary>
            <div>
                <ul><li>Two-center cross-sectional study w/ 228 CeD children demonstrated older mean age at menarche compared to healthy individuals (13.13 vs. 12.15 years).</li><li>Some other studies found no difference in mean age at menarche.</li><li>Few studies, later menarche &amp; earlier menopause have been observed in untreated CeD compared to GFD-treated CeD.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Recommendation</strong></summary>
            <div>
                <ul><li>CeD is recommended for young women w/ amenorrhea or delayed menarche.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>First-Degree Relatives</strong></summary>
            <div>
                <ul><li>Heritability of CeD is high.</li><li>Increased prevalence of CeD in first- &amp; second-degree relatives.</li></ul>
                
        <details>
            <summary><strong>Studies</strong></summary>
            <div>
                <ul><li>Evaluated 54 studies &amp; documented pooled prevalence of CeD of 7.5% in first-degree relatives.</li><li>Reported prevalence of 2.3% in CeD in second-degree relatives.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Recommendations</strong></summary>
            <div>
                <ul><li>Screening for CeD in first-degree relatives of patients w/ CeD.</li><li>Further research is necessary before recommending screening for second-degree relatives.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Discussion</strong></summary>
            <div>
                <ul><li>Paper aims to provide overview of screening process for CeD in high-risk groups.</li><li>Screening recommended in diseases mimicking CeD (IBD &amp; MC), as well as in high-risk groups such as first-degree relatives &amp; patients w/ autoimmune diseases.</li><li>Patients displaying symptoms &amp; signs suggestive of CeD should undergo CeD investigation, although this falls outside realm of traditional screening.</li></ul>
                
        <details>
            <summary><strong>Cost-Effectiveness Research</strong></summary>
            <div>
                <ul><li>More cost-effectiveness research on cut-offs for CeD screening is needed.</li><li>Applying cut-off level for undiagnosed CeD implies that screening recommendations could change.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Increase Case Finding</strong></summary>
            <div>
                <ul><li>Increase in incidence &amp; prevalence of CeD in many countries, efforts should be made to increase case finding for CeD.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>WHO Criteria</strong></summary>
            <div>
                <ul><li>WHO mandates fulfillment of criteria for mandatory general screening.</li><li>Criteria can help readers determine which high-risk groups should undergo screening.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>WHO Criteria Met</strong></summary>
            <div>
                <ul><li>CeD is well-defined (criterion I).</li><li>Screening tests for CeD are simple, safe, &amp; accurate (II).</li><li>Screening for CeD seems culturally acceptable worldwide (III).</li><li>Treatment is readily available (GFD) (IV).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>WHO Criteria Not Fully Met</strong></summary>
            <div>
                <ul><li>WHO suggests screening should only be performed in diseases for which clinical detection is difficult (V).</li><li>Unclear whether detecting undiagnosed CeD will prevent complications (VI) or whether testing &amp; treatment is cost-effective in patients w/ asymptomatic CeD (VII).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Remaining Questions</strong></summary>
            <div>
                <ul><li>Many questions remain regarding CeD screening.</li><li>Strict GFD may prevent development of other auto-immune disorders. This could be used as rationale for implementing early screening.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Comorbidities and Mechanisms</strong></summary>
            <div>
                <ul><li>Comorbidities may be linked to various mechanisms.</li><li>Mucosal damage can lead to malnutrition, resulting in nutritional deficiencies that underlie conditions such as osteopenia &amp; fatigue.</li><li>Shared genetic background has been well established for T1DM, w/ similar assumptions for other conditions.</li><li>Inflammation can serve as a trigger for additional comorbidities, such as IBD.</li><li>Shared symptoms can serve as a catalyst for investigations into CeD, as evidenced in cases of IBS.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Screening Recommendations</strong></summary>
            <div>
                <ul><li>Review focused on screening of high-risk groups w/ comorbidities. Not all of these patients require screening unless they are symptomatic.</li><li>Evidence for screening is strong: first-degree relatives. Pooled prevalence of CeD was 7.5% in first-degree relatives, w/ siblings showing highest rates.</li><li>Testing family members for gluten sensitivity presents unique challenges ∵ potential lower gluten consumption, ↑ risk of false-negative screening results.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Repeated Screening</strong></summary>
            <div>
                <ul><li>Recommendation for repeated screening for CeD applies only to patients w/ T1DM, justified by two factors: T1DM often occurs at young age, so individuals are still at high risk of developing CeD later in life &amp; prevalence of undiagnosed CeD may be higher in T1DM than in most other diseases analyzed in review.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Current Guidelines</strong></summary>
            <div>
                <ul><li>Most current guidelines recommend conducting CeD screening for numerous conditions.</li><li>Indications for screening should be broad, w/ emphasis on identifying aggressive cases &amp; symptomatic CeD patients. In these specific patients, a diagnosis can provide relief from celiac symptoms, although impact of diagnosing CeD on life expectancy &amp; QoL remains uncertain.</li><li>Need for data on cost-effectiveness of CeD.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Economic Burden</strong></summary>
            <div>
                <ul><li>Several papers have recently investigated economic burden of CeD, both pre- &amp; post-diagnosis, particularly in terms of health care costs, productivity loss among patients in workforce &amp; school, drug costs, as well as prognosis of undiagnosed &amp; asymptomatic CeD.</li><li>No evidence supporting mass screening.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Limitations</strong></summary>
            <div>
                <ul><li>Space &amp; scope to discuss individual disorders &amp; CeD screening were limited.</li><li>Many studies included in review were performed in Europe or North America. Further research from other regions is necessary, as screening recommendations may vary based on prevalence of CeD in general population.</li><li>Lack of specific data on cost-benefit analysis of screening.</li><li>Need for more data on screen-detected CeD &amp; QoL.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Conclusion</strong></summary>
            <div>
                <ul><li>Screening for CeD should be considered for broad spectrum of disorders.</li><li>Screening tests are safe &amp; valid; however, they should be performed according to strict principles prioritizing transparency of benefits to patients &amp; society.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Table 1. Guidelines for identifying populations at risk for CeD (high-risk individuals) and in special situations</strong></summary>
            <div>
                <ul><li>Summarizes guidelines for identifying populations at risk for CeD (high-risk individuals) and in special situations</li></ul>
                
        <details>
            <summary><strong>High-risk individuals</strong></summary>
            <div>
                <ul><li>Individuals exhibiting symptoms related to CeD or having clinical conditions potentially linked to the disorder (e.g., first-degree relatives of celiac patients or having coexisting autoimmune disorders).</li></ul>
                
        <details>
            <summary><strong>Comment on diagnostics</strong></summary>
            <div>
                <ul><li>The conventional approach is testing for IgA tTG antibodies plus total IgA concentration, followed by an upper endoscopy in cases of positive serology. However, there is growing evidence supporting a non-biopsy diagnosis. A serological approach may be considered in cases of repeatedly high levels of IgA tTG antibodies.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Undergoing endoscopy for any reason</strong></summary>
            <div>
                <ul><li>Typical duodenal endoscopic signs of CeD are evident.</li></ul>
                
        <details>
            <summary><strong>Comment on diagnostics</strong></summary>
            <div>
                <ul><li>Obtain a sufficient number of biopsies. Subsequently, CeD-specific serology may serve as a confirmatory diagnostic test.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Selective IgA deficiency</strong></summary>
            <div>
                <ul><li>It is estimated that ≥6% of individuals with this deficiency also have CeD.</li></ul>
                
        <details>
            <summary><strong>Comment on diagnostics</strong></summary>
            <div>
                <ul><li>IgG serology (IgG tTG/IgG DGP antibodies) is needed for diagnosis.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Seronegative CeD</strong></summary>
            <div>
                <ul><li>This condition is rare among CeD patients (1-5%). In these cases, IgG and IgA serology results are negative, but HLA DQ2/DQ8 is positive.</li></ul>
                
        <details>
            <summary><strong>Comment on diagnostics</strong></summary>
            <div>
                <ul><li>Duodenal biopsies should be performed.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Table 2: Disorders at high risk of celiac disease</strong></summary>
            <div>
                <ul><li>Summarizes disorders at high risk of celiac disease, including gastrointestinal, liver/pancreas/spleen, endocrinological, dermatological, neurological, gynecological, and genetic conditions.</li></ul>
                
        <details>
            <summary><strong>Gastrointestinal disorders</strong></summary>
            <div>
                <ul><li>Lists gastrointestinal disorders and recommendations for CeD screening.</li></ul>
                
        <details>
            <summary><strong>Eosinophilic esophagitis</strong></summary>
            <div>
                <ul><li>No screening recommended.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Autoimmune atrophic gastritis</strong></summary>
            <div>
                <ul><li>Yes, screening recommended.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Irritable bowel syndrome (IBS)</strong></summary>
            <div>
                <ul><li>Yes, screening recommended.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Inflammatory bowel disease (IBD)</strong></summary>
            <div>
                <ul><li>Yes, screening recommended.</li></ul>
                
        <details>
            <summary><strong>Authors&#x27; Comment</strong></summary>
            <div>
                <ul><li>Screening is not needed during follow-up of IBD if the patient responds well to treatment.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Microscopic colitis</strong></summary>
            <div>
                <ul><li>Yes, screening recommended.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Liver/Pancreas/Spleen disorders</strong></summary>
            <div>
                <ul><li>Lists liver, pancreas, and spleen disorders and recommendations for CeD screening.</li></ul>
                
        <details>
            <summary><strong>Unexplained pancreatic enzyme abnormalities</strong></summary>
            <div>
                <ul><li>No screening recommended.</li></ul>
                
        <details>
            <summary><strong>Authors&#x27; Comment</strong></summary>
            <div>
                <ul><li>Scarce and contradictory evidence on whether CeD is overrepresented in this group of patients.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Idiopathic pancreatitis</strong></summary>
            <div>
                <ul><li>Yes, screening recommended.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Unexplained liver enzyme abnormalities</strong></summary>
            <div>
                <ul><li>Yes, screening recommended.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Autoimmune hepatitis</strong></summary>
            <div>
                <ul><li>Yes, screening recommended.</li></ul>
                
        <details>
            <summary><strong>Authors&#x27; Comment</strong></summary>
            <div>
                <ul><li>Screening should ideally be carried out before the patient with AIH has received steroids or immunosuppressives.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Primary biliary cholangitis</strong></summary>
            <div>
                <ul><li>Yes, screening recommended.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Hyposplenism or functional asplenia accompanied by severe bacterial infections</strong></summary>
            <div>
                <ul><li>Yes, screening recommended.</li></ul>
                
        <details>
            <summary><strong>Authors&#x27; Comment</strong></summary>
            <div>
                <ul><li>Screening should be performed if the patient has also suffered from severe bacterial infections, in particular, those associated with encapsulated bacteria.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Endocrinological disorders</strong></summary>
            <div>
                <ul><li>Lists endocrinological disorders and recommendations for CeD screening.</li></ul>
                
        <details>
            <summary><strong>Type 1 Diabetes mellitus (T1DM)</strong></summary>
            <div>
                <ul><li>Yes, screening recommended.</li></ul>
                
        <details>
            <summary><strong>Authors&#x27; Comment</strong></summary>
            <div>
                <ul><li>Repeat screening in CeD-negative T1DM patients 2 and 5 years after T1DM diagnosis.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Hashimoto’s thyroiditis and Grave’s disease</strong></summary>
            <div>
                <ul><li>Yes, screening recommended.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Sjögren’s syndrome</strong></summary>
            <div>
                <ul><li>Yes, screening recommended.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Osteopenia and osteoporosis</strong></summary>
            <div>
                <ul><li>No screening recommended.</li></ul>
                
        <details>
            <summary><strong>Expert opinion</strong></summary>
            <div>
                <ul><li>#</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Dermatological disorders</strong></summary>
            <div>
                <ul><li>Lists dermatological disorders and recommendations for CeD screening.</li></ul>
                
        <details>
            <summary><strong>Dermatitis herpetiformis</strong></summary>
            <div>
                <ul><li>Yes, screening recommended.</li></ul>
                
        <details>
            <summary><strong>Authors&#x27; Comment</strong></summary>
            <div>
                <ul><li>All patients diagnosed with DH should undergo a duodenal biopsy before initiating GFD.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Psoriasis</strong></summary>
            <div>
                <ul><li>No screening recommended.</li></ul>
                
        <details>
            <summary><strong>Expert opinion</strong></summary>
            <div>
                <ul><li>#</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Other dermatological and oral disorders</strong></summary>
            <div>
                <ul><li>No screening recommended.</li></ul>
                
        <details>
            <summary><strong>Expert opinion</strong></summary>
            <div>
                <ul><li>#</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Oral disorders</strong></summary>
            <div>
                <ul><li>Lists oral disorders and recommendations for CeD screening.</li></ul>
                
        <details>
            <summary><strong>Recurrent aphthous syndrome</strong></summary>
            <div>
                <ul><li>Yes, screening recommended.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Enamel defects</strong></summary>
            <div>
                <ul><li>Yes, screening recommended.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Neurological disorders</strong></summary>
            <div>
                <ul><li>Lists neurological disorders and recommendations for CeD screening.</li></ul>
                
        <details>
            <summary><strong>Epilepsy</strong></summary>
            <div>
                <ul><li>No screening recommended.</li></ul>
                
        <details>
            <summary><strong>Expert opinion</strong></summary>
            <div>
                <ul><li>#</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Unexplained ataxia</strong></summary>
            <div>
                <ul><li>Yes, screening recommended.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Peripheral neuropathy</strong></summary>
            <div>
                <ul><li>Yes, screening recommended.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Migraine</strong></summary>
            <div>
                <ul><li>No screening recommended.</li></ul>
                
        <details>
            <summary><strong>Expert opinion</strong></summary>
            <div>
                <ul><li>#</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Gynecological disorders</strong></summary>
            <div>
                <ul><li>Lists gynecological disorders and recommendations for CeD screening.</li></ul>
                
        <details>
            <summary><strong>Infertility</strong></summary>
            <div>
                <ul><li>No screening recommended.</li></ul>
                
        <details>
            <summary><strong>Expert opinion</strong></summary>
            <div>
                
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Recurrent spontaneous abortions</strong></summary>
            <div>
                <ul><li>No screening recommended.</li></ul>
                
        <details>
            <summary><strong>Expert opinion</strong></summary>
            <div>
                
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Delayed menarche</strong></summary>
            <div>
                <ul><li>Yes, screening recommended.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Premature menopause</strong></summary>
            <div>
                <ul><li>Yes, screening recommended.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Genetic conditions</strong></summary>
            <div>
                <ul><li>Lists genetic conditions and recommendations for CeD screening.</li></ul>
                
        <details>
            <summary><strong>Down syndrome</strong></summary>
            <div>
                <ul><li>Yes, screening recommended.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Turner syndrome</strong></summary>
            <div>
                <ul><li>Yes, screening recommended.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Williams syndrome</strong></summary>
            <div>
                <ul><li>Yes, screening recommended.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Other disorders</strong></summary>
            <div>
                <ul><li>Lists other disorders and recommendations for CeD screening.</li></ul>
                
        <details>
            <summary><strong>Chronic fatigue syndrome</strong></summary>
            <div>
                <ul><li>Yes, screening recommended.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>IgA nephropathy</strong></summary>
            <div>
                <ul><li>Yes, screening recommended.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>IgA deficiency</strong></summary>
            <div>
                <ul><li>Yes, screening recommended.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>First-degree relatives, even if asymptomatic</strong></summary>
            <div>
                <ul><li>Yes, screening recommended.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Mass screening in the general population</strong></summary>
            <div>
                <ul><li>No screening recommended.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Figure 1: Disorders associated with CeD</strong></summary>
            <div>
                <ul><li>Graphical representation of disorders associated with CeD.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
    </div>
    
</div>


<script>
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');

    // Close all
    allDetails.forEach(detail => detail.removeAttribute('open'));

    // Open based on depth
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') depth++;
            parent = parent.parentElement;
        }
        if (depth < level) detail.setAttribute('open', '');
    });
}

// Automatically open to level 1 on page load
window.addEventListener('DOMContentLoaded', () => {
    setMindmapLevel(1);
});

function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;

    const onMouseDown = (e) => {
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };

    const elementDrag = (e) => {
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none"; // cancel centering transform
        elmnt.style.bottom = "auto"; // cancel fixed bottom
    };

    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };

    onMouseDown(event);
}
</script>


</body>
</html>
